ES2059457T3 - Utilizacion de bezafibrato para el tratamiento de la diabetes. - Google Patents

Utilizacion de bezafibrato para el tratamiento de la diabetes.

Info

Publication number
ES2059457T3
ES2059457T3 ES88113831T ES88113831T ES2059457T3 ES 2059457 T3 ES2059457 T3 ES 2059457T3 ES 88113831 T ES88113831 T ES 88113831T ES 88113831 T ES88113831 T ES 88113831T ES 2059457 T3 ES2059457 T3 ES 2059457T3
Authority
ES
Spain
Prior art keywords
bezafibrate
treatment
diabetes
normolipidaemic
diabetes type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88113831T
Other languages
English (en)
Inventor
Walter Dr Rer Nat Beck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Application granted granted Critical
Publication of ES2059457T3 publication Critical patent/ES2059457T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PATENTE ABARCA EL USO DE BEZALFIBRATO PARA EL TRATAMIENTO DE DIABETES NORMOLIPIDEMICA TIPO II, ASI COMO SU USO PARA LA FABRICACION DE MEDICAMENTOS.
ES88113831T 1987-09-01 1988-08-25 Utilizacion de bezafibrato para el tratamiento de la diabetes. Expired - Lifetime ES2059457T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873729209 DE3729209A1 (de) 1987-09-01 1987-09-01 Verwendung von bezafibrat zur behandlung von diabetes

Publications (1)

Publication Number Publication Date
ES2059457T3 true ES2059457T3 (es) 1994-11-16

Family

ID=6334986

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88113831T Expired - Lifetime ES2059457T3 (es) 1987-09-01 1988-08-25 Utilizacion de bezafibrato para el tratamiento de la diabetes.

Country Status (16)

Country Link
US (1) US5304575A (es)
EP (1) EP0305890B1 (es)
JP (1) JP2647918B2 (es)
KR (1) KR890004690A (es)
AT (1) ATE95694T1 (es)
AU (1) AU610228B2 (es)
CA (1) CA1323575C (es)
DE (2) DE3729209A1 (es)
DK (1) DK472688A (es)
ES (1) ES2059457T3 (es)
HU (1) HU200687B (es)
IE (1) IE62189B1 (es)
IL (1) IL87566A0 (es)
PH (1) PH24568A (es)
PT (1) PT88383B (es)
ZA (1) ZA886459B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU4050797A (en) * 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
AU8588798A (en) * 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
FR2774591B1 (fr) * 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
US7151191B2 (en) 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
EP1714648A4 (en) * 2004-02-09 2010-05-26 Aska Pharm Co Ltd COMBINATION DRUGS
FR2898894B1 (fr) * 2006-03-24 2008-06-06 Genfit Sa Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations
US10098860B2 (en) * 2016-07-20 2018-10-16 Cipla Limited Bezafibrate for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2149070C3 (de) * 1971-10-01 1978-03-23 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel
JPS56145261A (en) * 1980-04-10 1981-11-11 Kaken Pharmaceut Co Ltd Novel oxyacetic acid derivative, its preparation, and lowering agent of lipid in blood comprising it as active ingredient

Also Published As

Publication number Publication date
CA1323575C (en) 1993-10-26
AU2158688A (en) 1989-05-25
DK472688D0 (da) 1988-08-24
KR890004690A (ko) 1989-05-09
AU610228B2 (en) 1991-05-16
JP2647918B2 (ja) 1997-08-27
ATE95694T1 (de) 1993-10-15
ZA886459B (en) 1989-05-30
IL87566A0 (en) 1989-01-31
DE3729209A1 (de) 1989-03-09
EP0305890A3 (en) 1990-08-22
IE62189B1 (en) 1994-12-28
EP0305890B1 (de) 1993-10-13
DE3884895D1 (de) 1993-11-18
PH24568A (en) 1990-08-03
US5304575A (en) 1994-04-19
HUT47427A (en) 1989-03-28
PT88383B (pt) 1992-10-30
EP0305890A2 (de) 1989-03-08
IE882529L (en) 1989-03-01
PT88383A (pt) 1989-07-31
HU200687B (en) 1990-08-28
DE3729209C2 (es) 1989-08-03
DK472688A (da) 1989-03-02
JPS6471813A (en) 1989-03-16

Similar Documents

Publication Publication Date Title
ES551711A0 (es) Un procedimiento para el tratamiento del cabello.
FI873363A0 (fi) Foerfarande foer framstaellning av laekemedel med antitumoeraktivitet.
ES2059457T3 (es) Utilizacion de bezafibrato para el tratamiento de la diabetes.
DE3878627T2 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
ES2053748T3 (es) Oxazoles y tiazoles para el tratamiento de la demencia senil.
ES2013631B3 (es) Metodo para el tratamiento de tejidos.
ES2058272T3 (es) Fluoxetina util para el tratamiento de la diabetes.
ES2017764B3 (es) Procedimiento para el tratamiento de celulas primarias utilizadas
ES2052650T3 (es) Derivados de la 2-pirimidinil-1-piperazina para el tratamiento del alcoholismo.
ES2033494T3 (es) Procedimiento para el tratamiento de efluentes que contienen cianuro y/u otras sustancias oxidables.
ES520218A0 (es) Un procedimiento para la preparacion de nuevos 2,3-diaril-5-halotiofenos.
ES2113345T3 (es) Tratamiento de la disfuncion cardiaca con la ayuda de compuestos 15-ceto-prostaglandina.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DK207086A (da) Anvendelse af dopaminagonister
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
ES2060606T3 (es) Utilizacion de derivados de oxazolidinonas 5-(fenil-sustituido) para el tratamiento de depresiones.
DE3774931D1 (de) Einrichtung zur gesteuerten waermebehandlung von weichenteilen.
ES2129401T3 (es) Uso de un compuesto terapeutico para el tratamiento de bronquitis.
DE3885846D1 (de) Kontrollierte Stromquelle.
ES553272A0 (es) Procedimiento para el tratamiento del material carnalitico
ES2019583B3 (es) Composicion para el tratamiento de infecciones.
KR890701578A (ko) 신규의 티오펜 화합물 및 그들의 제법
ES1004491Y (es) Horma para el tratamiento ortopedico de calzado.
MX9203089A (es) Composicion para el tratamiento de esquisofrenia.
DE3688742T2 (de) 2,2-Diphenoxy-N,N-dimethylaminoäthan zur Verbesserung der Sauerstoffversorgung des Gehirns.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 305890

Country of ref document: ES